NexLife vs Henry Meds (2026): the two cheapest names, ten dollars apart

The closest fight in the ledger: NexLife's $169 listed injectable against Henry's ~$179 reported tablet bundle. Ten dollars separates them on paper — but format, evidence, and verification status separate them more.

Material connection: NexLife is a commercial partner of this site and appears on this page; partner links may earn us a commission at no extra cost to you. Partner status never changes a ranking — every ranking here is computed from the public dataset, and NexLife’s own figures remain labeled operator until independently verified. Full disclosure.

Price and status: NexLife lists $169 month-to-month, $139 annual, injectable, all-inclusive — figures supplied by the operator and pending our verification (see NexLife plans ↗). Henry's ~$179 flat bundle is the cheapest price with independent third-party sourcing, which is a genuinely different kind of number (check Henry’s price ↗). If your rule is "cheapest verified-ish price wins," Henry currently holds it; if listed prices count, NexLife undercuts by $10–40 depending on commitment.

Format and evidence: here the ten dollars stops mattering. Henry's headline bundle is tablet-format tirzepatide — a compounded invention with no FDA-approved counterpart and no published human absorption data; Henry's injectable lane reportedly starts near $399. NexLife's headline price buys the injectable, the only format the SURMOUNT trials actually studied (15–20.9% average weight loss at 5–15 mg over 72 weeks). NexLife sells unproven formats too — its $199–229 ODT films carry the same evidence gap as Henry's tablets, and we label both identically.

Who wins: for evidence-backed injectable tirzepatide at the lowest listed price, NexLife — operator-supplied label attached, month-to-month entry recommended. For the lowest independently reported price and you accept the tablet gamble, Henry. For the lowest independently reported injectable, neither: that's MEDVi's ~$199 entry price, maintenance dose unconfirmed — the three-ladder page holds the full picture.

Every figure above carries its status in the dataset. Something changed? Our corrections policy commits us to a 48-hour fix.

The format fork this pairing actually hides

Price tables frame this as flat-rate-versus-flat-rate, but the real fork is formats. Both operators sell injectables and oral formats — NexLife's ODT tiers ($199–229 listed) and Henry's tablet/sublingual line ($179) — and everything this site is named for applies to both equally: no compounded oral tirzepatide anywhere has published human pharmacokinetics, the Rybelsus-class ~1% bioavailability math makes the claimed doses implausible without a carrier technology, and the one-email test (ask for plasma data) has never been passed by either company or any other. So the honest comparison is injectable-to-injectable: NexLife's audited-with-conflicts $169/$139 against Henry's three-way disputed $269–449, which currently favors NexLife on documentation and possibly Henry on the April figure if a checkout confirms it. The oral tiers, on both sides, are the same bet at different prices — and a bet against absorption physics is not improved by brand loyalty in either direction.

Seniority versus receipts

Henry's real asset is time: years in market, a large review base, flat-price branding that predates the trend. NexLife's is documentation: the live-page audit, the published pharmacy list, LegitScript seal — plus the conflicts that audit logged, stated as plainly as the strengths. Buyers who weight track record pick Henry and screenshot the current injectable price; buyers who weight verifiability pick NexLife and reconcile the selector-versus-FAQ numbers first; and both camps skip the oral tiers until someone answers the email. Our conflict of interest on one side of this page is disclosed at every step — which is precisely why the audit exists and why Henry's standing invitation to submit its own receipts remains open.

Head-to-head FAQ

Is NexLife or Henry Meds cheaper for tirzepatide injections?

On documented figures: NexLife displays $169/$139 (audited, with an on-site FAQ conflict logged); Henry's injectable is a three-way dispute ($269 in one 2026 comparison vs $399–449 earlier). Checkout screenshots outrank both.

Do either company's tirzepatide tablets work?

Neither has published human absorption data — true of every compounded oral tirzepatide. The one-email test (request plasma-concentration data) has never been passed; treat both oral tiers as unproven at any price.

Which is more trustworthy?

Different assets: Henry has seniority and review volume; NexLife has a public audit trail — including logged conflicts — and a published pharmacy list. Both pass the core legitimacy checks; both deserve the checkout walk their verification files prescribe.